Aprilbio Co. Ltd.
AprilBio Co., Ltd. develops long-acting type biobetter and antibody biologics. The company develops antibody drugs, double antibodies, long-acting antibody drugs, long-acting protein drugs, and ADC-applied antibodies. It is developing various products for use in the treatment of rare diseases, cancer, male infertility, autoimmune and inflammatory diseases. The company was founded in 2013 and is h… Read more
Aprilbio Co. Ltd. (397030) - Total Assets
Latest total assets as of September 2025: ₩97.02 Billion KRW
Based on the latest financial reports, Aprilbio Co. Ltd. (397030) holds total assets worth ₩97.02 Billion KRW as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Aprilbio Co. Ltd. - Total Assets Trend (2020–2024)
This chart illustrates how Aprilbio Co. Ltd.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Aprilbio Co. Ltd. - Asset Composition Analysis
Current Asset Composition (December 2024)
Aprilbio Co. Ltd.'s total assets of ₩97.02 Billion consist of 97.0% current assets and 3.0% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩3.35 Billion | 3.4% |
| Accounts Receivable | ₩1.47 Billion | 1.5% |
| Inventory | ₩0.00 | 0.0% |
| Property, Plant & Equipment | ₩1.20 Billion | 1.2% |
| Intangible Assets | ₩476.75 Million | 0.5% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how Aprilbio Co. Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Aprilbio Co. Ltd.'s current assets represent 97.0% of total assets in 2024, an increase from 92.8% in 2020.
- Cash Position: Cash and equivalents constituted 3.4% of total assets in 2024, down from 52.2% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is cash and equivalents at 3.4% of total assets.
Aprilbio Co. Ltd. Competitors by Total Assets
Key competitors of Aprilbio Co. Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Aprilbio Co. Ltd. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Aprilbio Co. Ltd. generates 0.28x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Aprilbio Co. Ltd. generates $ 20.09 in net profit.
Aprilbio Co. Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 14.63 | 3.76 | 36.27 |
| Quick Ratio | 14.63 | 3.76 | 36.27 |
| Cash Ratio | 0.00 | 0.33 | 0.00 |
| Working Capital | ₩87.56 Billion | ₩ 61.25 Billion | ₩ 65.36 Billion |
Aprilbio Co. Ltd. - Advanced Valuation Insights
This section examines the relationship between Aprilbio Co. Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 16.49 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 25.0% |
| Total Assets | ₩99.60 Billion |
| Market Capitalization | $678.93 Million USD |
Valuation Analysis
Below Book Valuation: The market values Aprilbio Co. Ltd.'s assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Aprilbio Co. Ltd.'s assets grew by 25.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Aprilbio Co. Ltd. (2020–2024)
The table below shows the annual total assets of Aprilbio Co. Ltd. from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩99.60 Billion | +24.96% |
| 2023-12-31 | ₩79.70 Billion | +12.15% |
| 2022-12-31 | ₩71.06 Billion | +15.79% |
| 2021-12-31 | ₩61.38 Billion | +216.21% |
| 2020-12-31 | ₩19.41 Billion | -- |